TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Response to SIRT+sorafenib and sorafenib treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baseline FEV1/FVC%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of Grade ≥2 radiation-induced pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Montreal Cognitive Assessment scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Residual Cylinder (CYL) ≤0.50 D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores for pain during IA injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: meaningful change in depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fat fraction in supraclavicular BAT depot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean maximum total point motion (MTPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of pro-inflammatory factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Trunk control ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative refractive cylinder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative corneal toricity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ORA (Ocular Response Analyzer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in headache parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure pain threshold of sternocleidomastoid muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average time to healing for the frontal sinus neo‐ostium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SNOT‐22 scores post‐surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: USPIT score post‐surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: protein yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spot numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intensities for 2-DE gels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diabetic peripheral neuropathy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: glycated hemoglobin A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of negative personal value system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of repetitions achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral for Rehabilitation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: increase in oxygenated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in deoxygenated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in oxidized cytochrome‐c‐oxidase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Network connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV prevention awareness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fecal calprotectin level less than 250 mcg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recall of the Eat Well @ IGA brand
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Agreement on continuing efforts to encourage healthy eating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ever having given birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: percent ever having had sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Power gain on the number of eQTL harboring genes (eGenes) discovered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of POCD at discharge from rehabilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of POCD three months after cognitive training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: self-rated history-taking skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: NfL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: composite of cardiovascular death, MI, stroke, and bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Potential Renal Acid Load (PRAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Net Endogenous Acid Production (NEAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in bacterial counts (log CFU/mL of P. gingivalis and T. forsythia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in hyperplastic index (HI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of trismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alignment in decision-making roles
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: procalcitonin clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H2S concentration values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean relative abundance of Tannerella forsythia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intrapartum stillbirth
Endpoint domain: Mortality/survival
Primary endpoint: SPRID0-8h improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PID improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCT caregiver stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IL‐1RA level in QFT‐GIT supernatant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: early newborn mortality
Endpoint domain: Mortality/survival
Primary endpoint: Adherence to malaria protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual MR at 1-month post-implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically relevant health improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of TS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bleeding on probing percentage (BOP%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Buccal recession (REC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operation time for first placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Risky sexual behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: anxiety degree
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Length of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitigation of fever, cough, and tachypnoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of lung involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in daily living disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in average back muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified DISCERN score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of days alive and out of hospital within 14 days
Endpoint domain: Mortality/survival
Primary endpoint: Mean CEA value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limits of mild dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limits of severe dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in interleukins 6 and 8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RMSE values between outer contours of implanted and planned bone blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: RMSE values between inner contours of graft block and original bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Duration of bone block trimming
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sexual health communication self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average fluid velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective norm scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical fatigue at 4-year follow-up
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Total physical activity levels 4 years post-baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT/NG prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of suicide reattempts
Endpoint domain: Adverse events/effects
Primary endpoint: Donor return rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean hemoglobin increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Framingham cardiovascular disease risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain at 24 hours post-TSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at 48 hours post-TSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MME consumption at 48 hours post-TSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating disorder risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute bioavailability of posaconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posaconazole unbound fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total GRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of errors in suturing tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fatigue and physical comfort levels
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: ΔE00 (color change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ra (roughness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enamel topography alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urine volume decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urea and creatinine clearances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1, 3 and 5-year mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: 2-hour post-prandial blood glucose test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Potentially inappropriate medications (PIMs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular tachycardia (VT) inducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular fibrillation threshold (VFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Salivary fluoride concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vesikari score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: total diarrhea period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 6-month BMI z-score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child's health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Child's emotional/behavioral problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent's depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effectiveness of ketamine for postoperative analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of ketamine for postoperative analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in professional fulfillment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Transition rate to chronic LBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACPA positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MACE (grade ≥ 3 CV AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Relative increase in creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postcontrast acute kidney injury
Endpoint domain: Adverse events/effects
Primary endpoint: NRS score for running
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: levels of fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: children's m-GI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: composite maternal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep-related impairment
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 24‐h urinary Na+ excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum Na+ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Opioid consumption rate within postoperative 12 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with more than 5 opioid injections within 72 h postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of participants who were symptom free at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bifidobacteria abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counts of Clostridioides difficile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fecal secretory IgA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: adequate sedation at 15 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative recall improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower liver fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Electromyogram recordings in the trapezius muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Low-frequency/high-frequency ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: drug survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local tumor progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Herpes Zoster (HZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: total time for the time trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synovial hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Prostatic Symptoms Score (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in IL-8 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in IL-13 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in TNF-α concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 1RM estimation precision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAP threshold shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal CAP amplitude reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inner hair cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight/Body Mass Index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptomatic improvement as measured by BPRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific airway volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Brody index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in CGI-I for walking ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in MSIS-29 physical impact score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4 count augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Abstinence from smoking for the past 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of re-infection
Endpoint domain: Adverse events/effects
Primary endpoint: Virologically confirmed RSV illnesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lower respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fear of Falling (FOF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall adverse event rates
Endpoint domain: Adverse events/effects
Primary endpoint: time to first cigarette
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quitting self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduction in arousals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shorter latency to sleep stage N3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shorter self-reported time awake after sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of case management intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of management strategies for RPI
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: In-person follow-up rates within 7 days of ED discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hair amount increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scalp condition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee extensor maximal torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: vastus lateralis muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Relief of episodic breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPM effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes